TACT411 explained

Class:Monoamine transporter modulator; Serotonin 5-HT1B receptor modulator
Synonyms:TACT-411

TACT411 is a monoamine transporter modulator and serotonin 5-HT1B receptor modulator which is under development for the treatment of alcohol use disorder, anorexia, and binge-eating disorder.[1] [2] It is being developed by Tactogen. As of the first quarter of 2025, the drug is in the preclinical research stage of development. The exact chemical structure of TACT411 does not yet appear to have been disclosed, but it may be a benzofuran like 5-MAPB, 6-MAPB, BK-5-MAPB, or BK-6-MAPB.[3]

See also

Notes and References

  1. Web site: Haichin M . Psychedelics Drug Development Tracker . Psychedelic Alpha . 2024 . 29 January 2025.
  2. Web site: Tactogen Inc – Pipeline . Tactogen Inc . 29 January 2025 . OUR PIPELINE: [...] COMPOUND: TACT411/833*. TARGETS: 5-HT1B & MATs. INDICATION: Alcohol Use Disorder. Prevalence: 13.9%. STATUS: Preclinical. COMPOUND: TACT411/833*. TARGETS: 5-HT1B & MATs. INDICATION: Anorexia / Binge Eating Disorder. Prevalence: 3.6%. STATUS: Preclinical. [...] *We will make a final decision among our lead candidates after completing IND-enabling studies. Alternate lead candidates include TACT 523..
  3. US . 20230150963 . . Advantageous benzofuran compositions for mental disorders or enhancement . 2023 May 18 . 2022 December 8 . 2022 December 8 . .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "TACT411".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2026, A B Cryer, All Rights Reserved. Cookie policy.